Be The Match BioTherapies and Cryoport announced a new strategic partnership. The collaboration will expand the capabilities of IntegriCell, a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. With cryopreservation facilities in the U.S. and EU, IntegriCell??

is poised to support decentralized and centralized manufacturing models, enabling and accelerating patient access to innovative new therapies. Through this partnership, the companies will provide global bioprocessing and cryopreservation support throughout the U.S. and Europe. The integrated solution combines Be The Match BioTherapies' world-class capabilities for donor identification and collection of high-quality starting material with Cryoport's cryopreservation, bioprocessing and industry leading global logistics capabilities.

The IntegriCell?? solution aims to deliver optimized cellular starting material by providing cell processing, ideally within 24 hours post-collection, using standardized bioprocessing and Cryopreservation protocols performed by experienced teams. This solution will provide cell and gene therapy researchers, developers and manufacturers with consistent starting materials cryopreserved to improve manufacturing slot utilization leading to increased yields bringing new cell and gene therapies to market faster and more affordably.